MedWatch

Novo Nordisk target price increased by five institutions

The target price for Novo Nordisk shares was raised by a number of large financial players over the Easter weekend.

Photo: Novo Nordisk / PR

Novo Nordisk received more than just chocolate eggs this Easter.

Five large financial institutions raised their target prices for shares in the pharmaceutical company, with large UK bank Barclays setting the highest target price after an increase from DKK 750 (USD 109) to DKK 850 (USD 123) per share. Its recommendation remains ”overweight.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs